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Abstract 
Background: Despite the widespread use and availability of rapidly acting anti-malarials, the fatality rate of severe 
malaria in sub-Saharan Africa remains high. Adjunctive therapies that target the host response to malaria infection 
may further decrease mortality over that of anti-malarial agents alone. Peroxisome proliferator-activated receptor-
gamma agonists (e.g. rosiglitazone) have been shown to act on several pathways implicated in the pathogenesis of 
severe malaria and may improve clinical outcome as an adjunctive intervention.
Methods: In this study, the safety and tolerability of adjunctive rosiglitazone in paediatric uncomplicated malaria 
infection was evaluated in Mozambique, as a prelude to its evaluation in a randomized controlled trial in paediatric 
severe malaria. The study was a prospective, randomized, double-blind, placebo-controlled, phase IIa trial of rosigli-
tazone (0.045 mg/kg/dose) twice daily for 4 days versus placebo as adjunctive treatment in addition to Mozambican 
standard of care (artemisinin combination therapy  Coartem®) in children with uncomplicated malaria. The primary 
outcomes were tolerability and safety, including clinical, haematological, biochemical, and electrocardiographic 
evaluations.
Results: Thirty children were enrolled: 20 were assigned to rosiglitazone and 10 to placebo. Rosiglitazone treatment 
did not induce hypoglycaemia nor significantly alter clinical, biochemical, haematological, or electrocardiographic 
parameters.
Conclusions: Adjunctive rosiglitazone was safe and well-tolerated in children with uncomplicated malaria, permit-
ting the extension of its evaluation as adjunctive therapy for severe malaria.
The trial is registered with Clinicaltrials.gov, NCT02694874
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Background
Malaria causes an estimated 212 million infections and 
429,000 deaths annually [1]. Following the demonstra-
tion of the superiority of intravenous artesunate com-
pared to quinine, artesunate has become the standard of 
care for severe malaria in both adults and children [2, 3]. 
However, in spite of its improved efficacy over quinine, 
case fatality rates for severe malaria remain high, ranging 
from 8.5 to 30% [2, 3]. In addition, substantial post-severe 
malaria morbidity persists with long-term neurocogni-
tive impairments, such as deficits in attention, memory, 
speech, and language reported in up to one-third of chil-
dren surviving severe malaria [4–14]. Both parasite and 
host determinants contribute to the pathobiology of 
severe malaria. The host immune response plays a cen-
tral role in the onset, severity and outcome of malaria 
infections, and this has accelerated the search for immu-
nomodulatory adjunctive therapies that could improve 
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clinical outcome. To date, several putative adjunctive 
strategies have been tested in severe malaria, however 
with disappointing results [15, 16].
Peroxisome proliferator-activated receptor-gamma 
(PPARγ) is a member of the family of nuclear hormone 
receptors that function as ligand-activated transcription 
factors via their heterodimerization with another nuclear 
receptor, retinoic X receptor (RXR) [17–19]. PPARγ ago-
nists are promising candidates for adjunctive malaria 
treatment as they have been reported to have anti-
inflammatory, anti-oxidant, and neuroprotective prop-
erties [19–24]. The PPARγ agonist rosiglitazone is in the 
thiazolidinedione (TZD) class of drugs and is approved 
for the treatment of type II diabetes [25]. Rosiglitazone 
acts by increasing insulin sensitivity rather than increas-
ing insulin levels, does not induce hypoglycaemia, and 
has an established safety profile in adults [25–29].
Rosiglitazone has been shown to enhance mac-
rophage phagocytosis of Plasmodium falciparum para-
sitized erythrocytes, and to reduce parasite-induced 
pro-inflammatory cytokine secretion from monocytes 
and macrophages in  vitro [30]. In a pre-clinical in  vivo 
model of experimental cerebral malaria (ECM), rosiglita-
zone improved survival over artesunate alone, enhanced 
parasite clearance, reduced systemic inflammation and 
endothelial activation, prevented vascular leak, enhanced 
neuroprotective pathways, and protected mice from 
malaria-induced cognition and motor impairments [22, 
31]. In light of these promising pre-clinical results, a ran-
domized double-blind placebo controlled trial was con-
ducted in young adults with uncomplicated malaria on 
the Thai–Cambodian border [32]. In this randomized 
trial, rosiglitazone was safe and well tolerated, and 
led to significantly improved parasite clearance times, 
lower levels of pro-inflammatory mediators, evidence of 
enhanced endothelial quiescence, and increased levels of 
the neuroprotective mediator brain-derived neurotropic 
factor (BDNF) [22, 32].
Together, these results support the hypothesis that 
adjunctive rosiglitazone may improve outcomes in 
patients with severe malaria. Since the majority of severe 
malaria and associated deaths occur in children under 
5  years of age in sub-Saharan Africa, we conducted a 
phase IIa safety and tolerability trial in Mozambican chil-
dren with uncomplicated malaria, as a prelude to under-
taking a randomized trial in children with severe malaria.
Methods
Study design and participants
This was a prospective, parallel arm, unequally ran-
domized, placebo-controlled, double-blind trial of 
rosiglitazone versus placebo, in 30 Mozambican chil-
dren with uncomplicated malaria. All children received 
the Mozambican standard of care for uncomplicated 
malaria  (Coartem® Dispersible; artemether–lumefan-
trine 20  mg/120  mg, Novartis) with dosage determined 
by body weight, twice daily as recommended by National 
guidelines [33]. An unequal randomization list (2:1, in 
favour of rosiglitazone) was generated using blocks of 
3, using the free online randomization software Sealed 
Envelope™ (https://www.sealedenvelope.com/). Ran-
domization codes were placed inside individual sealed 
envelopes that were opened only by the nursing staff 
responsible for the administration of the drug. The 
remaining investigators were blind to the allocated inter-
vention. All laboratory tests and statistical analyses were 
performed blinded to treatment group. Enrollment took 
place between February and March 2016.
Ethical considerations
This study was reviewed and approved by the Mozam-
bican National Bioethics Committee (CNBS) (Ref. 
230/CNBS/15), the pharmaceutical department of the 
Mozambican Ministry of Health (Ref. 374/380/DF2016), 
the Clinical Research Ethics Committee of the Hospital 
Clínic, Barcelona, Spain (Ref. HCB/2015/0981), and the 
University Health Network Research Ethics Commit-
tee, Toronto, Canada (UHN REB Number 15-9013-AE). 
All research was conducted according to the principles 
expressed in the Declaration of Helsinki. The trial was 
registered with ClinicalTrials.gov on 9 December 2015, 
NCT02694874. All participants and their parents/legal 
guardians were given detailed oral and written informa-
tion about the trial, and children were recruited only 
after a written informed consent was signed by their par-
ents/legal guardians. Verbal assent was obtained from 
children over the age of 8.
Study setting, inclusion and exclusion criteria
The trial was conducted by the Centro de Investigação 
em Saúde de Manhiça (CISM) at the Manhiça District 
Hospital (MDH), in southern Mozambique. A detailed 
description of CISM may be found elsewhere [34]. In 
Mozambique, malaria transmission is perennial, with 
a seasonal peak from November to April [35]. Parents/
caregivers of children presenting to MDH were asked 
to participate in the trial and were screened for eligibil-
ity. Children, aged 1–12 years, were included in the study 
if they were positive for P. falciparum by microscopy, 
whereby a thick blood film confirmed malaria infec-
tion with parasitaemia >2500 parasites/μL. Children 
were excluded if they were known to have any known 
pre-existing illness (including neurological or neurode-
generative disorders, cardiac, renal or hepatic disease, 
diabetes, epilepsy, cerebral palsy), presented any reason 
for hospitalization, or if they had clinical or laboratory 
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evidence of severe malaria (including severe anaemia, 
hypoglycaemia, acidosis, repeated seizures, prostration, 
impaired consciousness, respiratory distress, or age-
adjusted tachypnea). Children receiving any therapy with 
potential anti-malarial activity (including cotrimoxazole), 
or treatment with a TZD were also excluded. Patients 
were approached after voluntarily presenting to MDH 
as part of routine care, and no financial incentives were 
provided.
Intervention
Rosiglitazone  (Avandia®, GlaxoSmithKline) and an 
identical looking placebo manufactured at the Hospital 
Clínic’s pharmacology department in Barcelona, Spain, 
were packaged and labelled to ensure blinding of study 
staff and hospital personnel. Children received either 
rosiglitazone (0.045  mg/kg/dose) or placebo twice daily 
for 4 days [36]. This dose was based on the maximal dose 
used by the manufacturer in the pediatric evaluation of 
rosiglitazone in children 10–17 [36]. The study medica-
tion was administered at the hospital, within the Clini-
cal Trials Unit, by authorized members of the study team 
only. The study intervention (rosiglitazone or placebo) 
was started together with the first dose of artemether–
lumefantrine. The interventions were administered orally. 
If any patient vomited or otherwise expelled the medica-
tion within 5 min of administration, the patient would be 
retreated. Rosiglitazone and placebo tablets were crushed 
and administrated as a powder mixed in water.
Treatment follow‑up and laboratory procedures
Following documentation of informed consent, par-
ticipants had an initial targeted physical examination 
performed by the study physician. Anthropomorphic 
measures were calculated upon admission using the 
WHO AnthroPlus Software version 1.0.4 for children 
0–19 years old [37]. A blood sample was taken at base-
line and prior to the administration of the study inter-
vention, for malaria diagnosis by microscopy, and 
haematological (haemoglobin, haematocrit, platelets, 
white cell full blood count) and biochemical (renal and 
liver function, glucose and lactate) evaluations. For a 
strict monitoring of glycaemia, finger-prick samples for 
glucose monitoring were obtained on admission, every 
6 h for the first 48 h, and then every 24 h until discharge, 
and again at the day 7 and day 14 follow-up visits. Hypo-
glycaemia was defined as blood glucose <2.5  mmol/L 
(45  mg/dL) in an adequately-nourished child accord-
ing to WHO definition [37]. Lactate was monitored on 
admission, every 12 h for the first 24 h, and then every 
24 h until discharge, and again at the day 7 and day 14 
follow-up visits. Biochemistry, including aspartate ami-
notransferase (AST), alanine aminotransferase (ALT), 
urea, creatinine, lactate dehydrogenase (LDH), and indi-
rect and direct bilirubin, were assessed in venous blood 
every 24  h from admission until discharge and once 
again on day 7 follow-up. Venous blood extraction for 
haematology was performed every 24 h from admission 
until discharge and again on day 7 and 14 follow-up. 
Finally, venous blood extraction for biomarker analy-
sis was performed on admission, 12, 24, 36, 48, 60, 72, 
and 84 h after admission, and again at the day 7 and 14 
follow-up visits. Electrocardiographic monitoring was 
performed using a portable  12 lead electrocardiogram 
(ECG) machine (Cardioline ECG100+; AB Medica 
Group SA) at screening (before administration of study 
interventions), on day 1 (24 h after admission and after 
the second dose of study intervention), and on day 4 
(after the last dose of study intervention). An additional 
ECG was conducted on day 7, only if abnormalities were 
recorded on day 4. The study clinicians reviewed all ECG 
tracings immediately after they were obtained, paying 
special attention to the QT segment length and poten-
tial prolongations from baseline. All children were kept 
at the health facility for the 4-day dosing period, despite 
being uncomplicated malaria cases. The mother/guard-
ian was asked to return with the child for scheduled vis-
its on day 7 and 14 post-treatment, or if any symptoms 
occurred. On each visit, a physical examination was per-
formed by the study clinicians, vital signs were recorded, 
and body temperature measured.
Outcomes
The primary outcome was safety and tolerability over the 
first 84 h of hospital admission as determined by clinical, 
biochemical, haematological, and electrocardiographic 
observations according to specific pre-defined local ref-
erence ranges. Adverse events (AEs) and serious adverse 
events (SAEs) were recorded and monitored throughout 
the study.
Statistical analyses
Statistical analyses were performed with SPSS v.24 and 
Graph Pad Prism v.7. Differences between groups were 
assessed using the Fisher’s exact test for categorical 
demographic values, and by t test or Mann–Whitney U 
test (two-tailed) for clinical laboratory data based on the 
distribution of the data. Glucose measures at each time 
point were compared using a Mann–Whitney U test 
(two-tailed).
Mann–Whitney U tests were used to compare the 
median changes from baseline for glucose, AST, ALT, 
haemoglobin and haematocrit between the two treat-
ment arms. Mean haematocrit and haemoglobin values 
were compared using ANOVA. A p value <0.05 was con-
sidered as statistically significant.
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Results
The trial’s flow diagram is shown in Fig. 1. Baseline char-
acteristics were similar between the two treatment groups 
(Table  1). Clinical monitoring of vital signs, including 
respiratory rate, heart rate, blood pressure, and oxygen 
saturation levels did not differ between groups. All study 
patients, irrespective of randomization group, had an 
eventless clinical course. No adverse drug reactions were 
observed, and no patient vomited in either group. No 
patient enrolled in this study had a SAE or died.
Treatment with rosiglitazone did not induce hypogly-
caemia, and all glucose were above the lower blood glu-
cose threshold of 2.5 mmol/L (Fig. 2). Median changes in 
glucose levels between baseline and day 14 did not sig-
nificantly differ between the placebo and rosiglitazone 
arms (1.2 vs. 0.3  mmol/L, p =  0.52). Only one isolated 
lactate value out of the normal range (0–5 mmol/L) was 
observed in a rosiglitazone-treated patient at 24  h post 
recruitment (5.5  mmol/L) that stabilized without any 
additional treatment.
Only two values of AST were out of range (0–100 U/L). 
These were observed at baseline in two children receiving 
placebo. They spontaneously normalized and were not 
associated with any clinical symptoms or signs. Median 
changes in AST levels between baseline and day 7 did not 
significantly differ between placebo and treatment arms 
(3.5 vs. 7  U, p =  0.78). Nor was there a significant dif-
ference in median changes in ALT between placebo and 
rosiglitazone treated participants (3.5 vs. 11 U, p = 0.15) 
between baseline and day 7. For the remaining biochemi-
cal parameters, including urea, creatinine, LDH, direct or 
indirect bilirubin, no significant differences or trending 
abnormalities were observed.
Haematological adverse events were uncommon. Three 
children had a haemoglobin decrease >2 g/dL from their 
baseline values, and further two had a haemoglobin value 
Fig. 1 Study profile of 33 patients screened for eligibility for a randomized, placebo-controlled, phase IIa trial of adjunctive rosiglitazone for the 
treatment of uncomplicated malaria in children
Table 1 Patient characteristics on admission
Median [IQR] for non-normally distributed variables
Number (%) for categorical variables
Parasite density is represented as geometric mean {range}
a Mean (SD) for normally distributed variables
Placebo, N = 10 Rosiglitazone, 
N = 20
p
Female sex (%) 7 (70%) 11 (55%) 0.70
Age (years)a 8 (4.6, 9.1) 6.9 (4.7, 9.8) 0.92
Weight (kg) 21.5 [15.0, 24.8] 20.2 [16.1, 2.7] 0.87
Height (cm) 124.0 [101.0, 132.5] 115.0 [106.0, 131.5] 0.75
BMI/age −1.13 [−1.40, −0.37] −0.15 [−3.2, 0.24] 0.11
Weight-for-age Z 
score (WAZ)
−1.1 [−1.4, −0.73] −0.67 [−1.5, 0.81] 0.34
Temperature (oC) 38.3 [36.6, 39.1] 36.6 [36.1, 37.5] 0.07
Heart rate (bpm) 123.2 (15.58) 120.1 (14.6) 0.60
Glucose (mmol/L) 7.2 [5.3, 8.3] 5.9 [5.1, 7.3] 0.40
Lactate (mmol/L) 2.5 [2.1, 2.9] 1.9 [1.8, 3.2] 0.23
Haemoglobin (g/L) 10.1 (0.8) 10.1 (1.5) 0.99
Haematocrit (%) 30.1 (2.3) 30.4 (4.0) 0.83
Leukocytes (×109/L) 8.3 (3.0) 7.4 (2.5) 0.41
Platelets (×109/L) 96.3 (34.3) 131.8 (59.4) 0.09
AST (U/L) 53.8 (41.7) 36.4 (10.5) 0.08
ALT (U/L) 27.5 [5.3, 41.0] 33 [26, 36.8] 0.54
Urea (mg/dL) 12.5 [12.0, 17.3] 14.0 [13.0, 15.8] 0.67
Creatinine (µmol/L) 35.3 [30.7, 39.0] 31.2 [29.8, 42.8] 0.81
Parasite density 
(parasites/μL)
23,499 {4166, 55,491} 24,622 {3346, 91,869} 0.91
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below the 7  g/dL threshold; none were associated with 
clinical manifestations. Median changes in haemoglobin 
levels between baseline and day 14 did not significantly 
differ between the placebo and rosiglitazone arms (0.4 
vs. 0.7  g/L, p  =  0.56). Median changes in haematocrit 
levels between baseline and day 14 did not significantly 
differ between the placebo and rosiglitazone arms (0.4 
vs. 0.7 g/L, p = 0.56). There was no significant difference 
between the treatment groups on haematocrit or haemo-
globin levels (p = 0.13 and p = 0.12, respectively, Fig. 3). 
No differences in haematological parameters, including 
leukocytes, platelets or other components of the com-
plete blood cell count, were observed between groups.
Table 2 summarizes all ECG abnormalities found dur-
ing the study follow up. None of these events were associ-
ated with clinical findings or with the study intervention. 
No additional medication was administered to these 
patients. No patient had a QTc of more than 500 ms at 
any of the measured time points.
Mean parasite densities at baseline and throughout the 
study were similar between groups, (Fig. 4). Median time 
to parasite clearance was 33  h in both the rosiglitazone 
and placebo groups (p = 0.88).
Discussion
In this study, the safety and tolerability of rosiglitazone 
as an adjunctive therapy for the treatment of uncom-
plicated malaria was investigated, as a first step before 
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Fig. 3 Mean hematocrit and hemoglobin levels according to study group on admission (AD) and at each measured time point
Table 2 ECG abnormalities
These abnormalities were not clinically significant (NCS). QT corrected for heart rate using Fridericia’s method
Patient Treatment QTc baseline (ms) QTc maximum (ms) ECG findings
ROSI-002 Rosiglitazone 352 407 Increase of QtcF >50 ms on day 4, NCS
ROSI-007 Rosiglitazone 396 427 Increase of QtcF >50 ms on day 2, NCS. Finished on day 4
ROSI-008 Rosiglitazone 356 424 Increase of QtcF >50 ms on day 2, NCS. Continue on day 7, NCS
ROSI-009 Placebo 342 425 Increase of QtcF >50 ms on day 4 with associated bradycardia, NCS
Increase of QtcF >50 ms on day 7, NCS and without bradycardia
ROSI-010 Placebo 336 409 Increase of QtcF >50 ms on day 4, NCS. Finished on day 7
ROSI-012 Rosiglitazone 323 404 Increase of QtcF >50 ms on day 2, NCS. Finished on day 4
ROSI-014 Placebo 364 425 Left bundle branch block from screening, NCS
Increase of QtcF >50 ms on day 4, NCS. Finished on day 14
Bradycardia on day 4, NCS
ROSI-021 Placebo 361 414 Increase of QtcF >50 ms on day 4, NCS. Finished on day 7
ROSI-022 Placebo 349 402 Increase of QtcF >50 ms on day 4, NCS. Finished on day 7
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evaluating its efficacy in the treatment of severe paedi-
atric malaria and prevention of malaria-associated neu-
rocognitive complications. Although rosiglitazone has a 
well-established safety profile, and millions of doses have 
been administered to adults with type II diabetes mel-
litus [38], this was the first time that the drug was used 
(off-label) as an adjunct to standard malaria treatment 
in African children. For this reason, and in concordance 
with recommendations issued by the CNBS, 30 children 
with uncomplicated malaria were carefully followed, 
and assessed for a variety of haematological, biochemi-
cal, clinical, and electrocardiographic safety variables, 
to ensure that the drug was not associated with adverse 
events. Although rosiglitazone was found to be safe and 
well-tolerated in children with uncomplicated malaria 
it cannot be assumed that a similar safety profile would 
be observed in children with severe malaria. Any future 
studies investigating the use of rosiglitazone for this 
purpose will be required to include additional safety 
evaluations.
Hypoglycaemia is a common and life-threatening com-
plication of malaria [39], and drugs with negative effects 
on glycaemia levels would be problematic as adjuvant 
malaria therapies. Thus, particular attention was placed 
in assessing whether rosiglitazone would be associ-
ated with any glycaemia abnormalities in this popula-
tion. Rosiglitazone acts by increasing insulin sensitivity 
rather than increasing insulin levels, and therefore, it is 
unlikely to induce hypoglycaemia. Although our sample 
size was small, it was reassuring that none of the malaria 
infected participants displayed glycaemia levels below 
2.5  mmol/L, and glycaemia levels were similar between 
the treatment and placebo groups.
A second important aspect of this trial was to assess 
potential adverse cardiac events. Initial case–control 
studies of long-term use in elderly high-risk diabetic 
patients reported a potential increase in acute cardiac 
events [28]; however these studies had methodologi-
cal problems and recent reports from the USA Food 
and Drug Administration (FDA) have concluded that 
rosiglitazone is safe and was not associated with excess 
cardiovascular risk [28]. Importantly, as of June 2013, an 
FDA expert panel relaxed restrictions on this drug [29]. 
In agreement with these findings, no cardiac adverse 
events or increased risk over placebo were observed 
in a previous randomized trial in adults with uncom-
plicated malaria [32]. Similarly, and as anticipated for a 
paediatric non-diabetic patient population treated with 
a short course (4  days) of rosiglitazone, no cardiovas-
cular adverse events were observed in this study. Addi-
tionally, some oral artemisinin-based combinations have 
been reported to induce prolongation of the electrocar-
diogram’s QT interval, while malaria infection itself can 
increase the sympathetic tone of the heart, which mani-
fests as a shortening of the QT interval in ECG traces 
[40]. Repeated ECG measurements detected only a few 
electrocardiographic abnormalities, none of which were 
deemed related to the investigational drug. The incidence 
and clinical significance of these electrocardiographic 
abnormalities were equally distributed between the pla-
cebo and rosiglitazone groups.
Rosiglitazone has been reported to decrease mean hae-
moglobin and haematocrit in a dose-related fashion in 
adults, particularly when it is taken on a daily basis [41]. 
This potential effect needed to be evaluated in the con-
text of malaria, a disease often associated with decreases 
in haemoglobin levels. No major declines in haemoglo-
bin or haematocrit were observed in either study arm, 
and no significant interaction between the study arm and 
sampling time were observed for either haemoglobin or 
haematocrit.
Rosiglitazone, malaria, and many anti-malarial drugs 
can be associated with increases in hepatic transaminases 
[41–44]. In this trial, transaminase levels were monitored 
in addition to direct and indirect bilirubin, and no patient 
receiving rosiglitazone had levels outside of the normal 
range.
This study was not powered to evaluate efficacy end-
points of rosiglitazone. As such, the outcomes of the 
uncomplicated malaria participants recruited to evalu-
ate the safety and tolerability of the drug, may not be 
sufficiently informative of the potential that the drug 
has to impact the course of disease. Although increase 
parasite clearance times were previously observed in 
adult patients randomized to rosiglitazone in a previ-
ous randomized control trial these patients received 
atovaquone/proguanil [32]. Even with a study powered 
to study efficacy we may not see improved parasite clear-
ance times due to the fast clearance of early rings by 
artemisinins. There is limited pharmacokinetic–phar-
macodynamic data of rosiglitazone in children under the 
age of 10. These data would have added more reassurance 
regarding the safety of rosiglitazone in children and is a 
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limitation of the study. Further evaluation of rosiglita-
zone, when used as an adjunctive therapy in the context 
of severe malaria, will be required to explore its impact 
on pathways implicated in the pathogenesis and outcome 
of severe malaria.
Conclusion
This is the first report of rosiglitazone use in African 
children with an acute uncomplicated malaria infection. 
The safety and tolerability results, including no vomiting, 
no idiosyncratic drug reactions, and no serious adverse 
events support its continued evaluation as an adjuvant 
therapy in the treatment of severe paediatric malaria.
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